Richter's Syndrome clinical trials at UC Davis
1 research study open to eligible people
An Experimental Combination of Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab For Diffuse Large B-Cell Lymphoma
open to eligible people ages 18 years and up
This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving atezolizumab, gemcitabine, oxaliplatin, and rituximab may work better in treating patients with transformed diffuse large B-cell lymphoma.
Sacramento, California and other locations
Our lead scientists for Richter's Syndrome research studies include Joseph M. Tuscano.